Navigation Links
Neogen Launches Fully Quantitative Lateral Flow Test for DON
Date:1/3/2012

LANSING, Mich., Jan. 3, 2012 /PRNewswire/ -- Neogen Corporation has developed a new test for deoxynivalenol (DON) that combines the speed and simplicity of a lateral flow test with the fully quantitative precision of a more demanding testing method. The presence of the mold toxin DON in certain grains is a major concern to producers of animal feed and human food.

Neogen's new Reveal® Q+ for DON delivers precise results ranging from 0.3 to 6 parts per million (ppm) of DON after only 3 minutes, following an extraction procedure that only requires water. Reveal Q+ test strips are read in Neogen's AccuScan® III lateral flow test reader to deliver exact results.

"Reveal Q+ for DON is the fastest and easiest fully quantitative test available for DON," said Ed Bradley, Neogen's vice president for Food Safety. "This innovative technology yields more accurate and reproducible results than other testing methods for DON. Coupled with Neogen's AccuScan III portable, hand-held reader, the Reveal Q+ system objectively reads, analyzes and stores test results.

"The new Reveal Q+ products only add to Neogen's unmatched range of simple and accurate lateral flow, microwell, and immunoaffinity column mycotoxin testing options — all of which are backed by the best technical and R&D support in the industry," Bradley continued.

In September, Neogen launched Reveal Q+ for Aflatoxin, which delivers precise results ranging from 2 to 150 parts per billion (ppb) of aflatoxin after only 6 minutes.

Reveal Q+ testing products offer room temperature incubation of the test strip and room temperature storage of the test kit — eliminating the need for an incubator and refrigeration space. The tests require minimal equipment to achieve precise results, and the aflatoxin test utilizes a simple, low-cost ethanol extraction process. Ethanol often is the preferred extraction solvent of major grain handlers.

Neogen's AccuScan III hand-held reader provides an easy method to objectively read, store, and analyze results from Neogen's line of lateral flow tests. AccuScan provides a permanent record that can be incorporated into a company's food safety plan, such as HACCP.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.

 


'/>"/>
SOURCE Neogen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neogen Reports Second Quarter Results
2. Neogen Corporation Announces 2nd Quarter Results Conference Call
3. Neogen Reports First Quarter Revenue and Net Income Increases
4. Neogen Launches Fully Quantitative Lateral Flow Test for Aflatoxin
5. Neogen Reports 30% Increase in Net Income
6. Neogen Corporation Announces Year-End Results Conference Call
7. Neogen Acquires VeroMara from GlycoMar Ltd.
8. William T. Boehm Joins Neogens Board of Directors
9. Neogen Reports 27% Increase in Quarterly Net Income
10. Neogens Rapid Test for Salmonella enteritidis Receives FDA Approval
11. Neogen Names Quinlan as CFO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):